Sandoz H1 2026 net sales rise 9% to $3.01 billion, narrowly beating consensus

Sandoz reported half-year 2026 net sales of $3.01 billion on 5 August 2026, up 9% and narrowly above consensus. Biosimilar revenue drove the gain. The print offers the first hard data validating management's February guidance anticipating 2026 growth acceleration from recently launched biosimilars. A Capital Markets Day is set for 8 September 2026 in London.